NDA 019906 · Specgx LLC
Anafranil
Clomipramine Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Dec 29, 1989
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
4 Phase 3, 2 recruiting
FAERS reports
4,574
4,205 serious, 402 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of clomipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and...
What it is approved for
From the label in effect Nov 26, 2024.
INDICATIONS AND USAGE Anafranil ™ (clomipramine hydrochloride) Capsules USP is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of Anafranil for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking CMI experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. CMI-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of Anafranil for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 29, 1989 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDA
3 products under this application
- ANAFRANIL · CLOMIPRAMINE HYDROCHLORIDE 75MG · CAPSULE, ORAL · Prescription · TE AB
- ANAFRANIL · CLOMIPRAMINE HYDROCHLORIDE 25MG · CAPSULE, ORAL · Prescription · TE AB
- ANAFRANIL · CLOMIPRAMINE HYDROCHLORIDE 50MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clomipramine" as an intervention, any sponsor and status, largest first.
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature EjaculationPivotal-lookingStatus unknown
CTC Bio, Inc.Industry
NCT02571101 · 297 participants (planned) · Start Nov 2015 · Primary completion May 2016
Drug: CDFR0812-15/25mg; CDFR0812-15/50mg and 3 more · For: Premature Ejaculation
Sites: Goyang-si, South Korea; Pusan, South Korea; Seoul, South Korea · 9 sites in all
Severance HospitalAcademic, hospital or other
NCT02431845 · 200 participants (planned) · Start Jan 1, 2013 · Primary completion Dec 31, 2030
Drug: SSRIs · For: Obsessive-Compulsive Disorder
Sites: Seoul, South Korea
- Trial of PED-1 in Male Patients With Premature EjaculationPivotal-lookingCompleted
SymyooIndustry
NCT01439984 · 159 participants · Start Sep 2011 · Primary completion Jun 2012
Drug: Clomipramine · For: Premature Ejaculation
Sites: Goyang-si, South Korea; Uijeongbu-si, South Korea; Seoul, South Korea · 5 sites in all
- Efficacy of Antidepressants in Chronic Back PainPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT00964886 · 142 participants · Start Jan 2010 · Primary completion Dec 2014
Drug: desipramine hydrochloride; benztropine mesylate 0.125 mg daily and 1 more · For: Back Pain
Sites: San Diego, California
- Effect of Antidepressants on Back PainPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00018200 · 130 participants · Start Apr 1999 · Primary completion Dec 2003
Drug: Desipramine; Fluoxetine and 1 more · For: Back Pain; Sciatica
Sites: San Diego, California
- Treatment of Obsessive Compulsive Disorder in ChildrenPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT00074815 · 124 participants · Start Sep 2003 · Primary completion Nov 2009
Drug: Serotonin reuptake inhibitors management · For: Obsessive-Compulsive Disorder
Sites: Durham, North Carolina; Philadelphia, Pennsylvania; Providence, Rhode Island
- Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major DepressionPivotal-lookingTerminated
Hospital Universitari de BellvitgeAcademic, hospital or other
NCT01305707 · 104 participants · Start Jul 2009 · Primary completion Jul 2014
Drug: PHARMACOTHERAPY · For: Depression
Sites: Barcelona, Spain; L'Hospitalet de Llobregat, Spain; Sabadell, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction234
- somnolence217
- fall209
- off label use200
- tremor189
- nausea182
- coma180
- suicide attempt177
- intentional overdose176
- drug ineffective173
- anxiety167
- confusional state166
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 168 |
| 2005 | 121 |
| 2006 | 118 |
| 2007 | 139 |
| 2008 | 156 |
| 2009 | 153 |
| 2010 | 161 |
| 2011 | 192 |
| 2012 | 180 |
| 2013 | 169 |
| 2014 | 199 |
| 2015 | 221 |
| 2016 | 257 |
| 2017 | 261 |
| 2018 | 290 |
| 2019 | 304 |
| 2020 | 291 |
| 2021 | 190 |
| 2022 | 206 |
| 2023 | 248 |
| 2024 | 210 |
| 2025 | 169 |
| 2026 | 170 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Anafranil (Clomipramine HCl)
2024 spending
$1.0M
Beneficiaries
42
224 claims
Per beneficiary
$24,711
$35.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,390,951 |
| 2021 | $1,302,137 |
| 2022 | $1,373,335 |
| 2023 | $1,057,492 |
| 2024 | $1,037,850 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Dementia.
Butler R, Radhakrishnan R · BMJ Clin Evid 2012 · Systematic Review
- Dementia.
Warner JP, Butler R, Gupta S · BMJ Clin Evid 2010 · Systematic Review
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacotherapy for trichotillomania.
Hoffman J, Williams T, Rothbart R, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.
Skapinakis P, Caldwell DM, Hollingworth W, et al. · Lancet Psychiatry 2016 · Comparative Study, Systematic Review
Sponsor: Specgx LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.